Place of pegvisomant in acromegaly

Lancet

Volumn 358, Issue 9295, 2001, Pages 1743-1744

  Ho, Ken K Y ^a  

^a ST VINCENT S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE RECEPTOR STIMULATING AGENT; GROWTH HORMONE; MACROGOL; OCTREOTIDE; PEGVISOMANT; SOMATOMEDIN C; SOMATOSTATIN DERIVATIVE;

ACROMEGALY; CANCER RADIOTHERAPY; CONTROLLED STUDY; DIET RESTRICTION; DISEASE MARKER; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SAFETY; GROWTH HORMONE BLOOD LEVEL; HUMAN; HYPOPHYSIS TUMOR; LIVER DYSFUNCTION; MORTALITY; NEGATIVE FEEDBACK; NOTE; PRIORITY JOURNAL; TREATMENT OUTCOME; TUMOR GROWTH; TUMOR VOLUME;

EID: 0035944853     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(01)06839-8     Document Type: Note

References (12)

1. In vitro and in vivo studies of the antagonistic effects of human growth hormone analogs
2. Rational design of potent antagonists to the human growth hormone receptor
3. Long-acting growth hormones produced by conjugation with polyethylene glycol
4. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant
5. Binding and functional studies with the growth hormone receptor antagonist B2036-PEG (Pegvisomant) reveal effects of pegylation and evidence that it binds to a receptor dimer
6. Regulation of pulsatile growth hormone secretion in normal subjects and patients with acromegaly
7. Control of tumour size and disease activity during cotreatment with octreotide and the growth hormone receptor antagonist pegvisomant in an acromegalic patient
8. Determinants of clinical outcome and survival in acromegaly
9. Long-term mortality after transphenoidal surgery and adjunctive therapy for acromegaly
10. Criteria for cure of acromegaly: A consensus statement
11. Characterisation of 24-hour growth hormone secretion in acromegaly: Implications for diagnosis and therapy
12. Diagnosis of growth hormone deficiency in adults